Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
- Revenue in USD (TTM)1.86bn
- Net income in USD-40.29m
- Incorporated2008
- Employees1.15k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| argenx SE - ADR | 1.86bn | -40.29m | 35.07bn | 1.15k | -- | -- | -- | 18.87 | -0.8399 | -0.8399 | 30.57 | -- | -- | -- | -- | 1,619,085.00 | -- | -17.65 | -- | -19.79 | 89.56 | -- | -2.17 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
| Iqvia Holdings Inc | 15.32bn | 1.41bn | 35.30bn | 88.00k | 25.50 | 5.07 | 13.91 | 2.30 | 7.62 | 7.62 | 83.09 | 38.36 | 0.5762 | -- | 4.77 | 176,034.50 | 5.31 | 3.24 | 7.13 | 4.07 | 35.17 | 34.32 | 9.21 | 6.03 | -- | 3.43 | 0.6598 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 5.00m | 8.35% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 4.52m | 7.55% |
| Artisan Partners LPas of 30 Sep 2024 | 3.51m | 5.88% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 2.48m | 4.14% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 1.70m | 2.84% |
| Avoro Capital Advisor LLCas of 30 Sep 2024 | 1.24m | 2.07% |
| T. Rowe Price International Ltd.as of 30 Sep 2024 | 825.25k | 1.38% |
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 771.57k | 1.29% |
| RTW Investments LPas of 30 Sep 2024 | 654.43k | 1.09% |
| Bellevue Asset Management AGas of 30 Sep 2024 | 632.83k | 1.06% |
